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Abstract: The antitumor drug paclitaxel stabilizes microtubules and reduces their dynamicity, promoting mitotic arrest 
and eventually apoptosis. Upon assembly of the α /β-tubulin heterodimer, GTP becomes bound to both the α and β-
tubulin monomers. During microtubule assembly, the GTP bound to β-tubulin is hydrolyzed to GDP, eventually reach-
ing steady-state equilibrium between free tubulin dimers and those polymerized into microtubules. Tubulin-binding 
drugs such as paclitaxel interact with β-tubulin, resulting in the disruption of this equilibrium. In spite of several crys-
tal structures of tubulin, there is little biochemical insight into the mechanism by which anti-tubulin drugs target mi-
crotubules and alter their normal behavior. The mechanism of drug action is further complicated, as the description of 
altered β-tubulin isotype expression and/or mutations in tubulin genes may lead to drug resistance as has been described 
in the literature. Because of the relationship between β-tubulin isotype expression and mutations within β-tubulin, both 
leading to resistance, we examined the properties of altered residues within the taxane, colchicine and Vinca binding 
sites. The amount of data now available, allows us to investigate common patterns that lead to microtubule disruption 
and may provide a guide to the rational design of novel compounds that can inhibit microtubule dynamics for speciﬁ  c 
tubulin isotypes or, indeed resistant cell lines. Because of the vast amount of data published to date, we will only pro-
vide a broad overview of the mutational results and how these correlate with differences between tubulin isotypes. We 
also note that clinical studies describe a number of predictive factors for the response to anti-tubulin drugs and attempt 
to develop an understanding of the features within tubulin that may help explain how they may affect both microtubule 
assembly and stability.
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Introduction
Microtubules (MTs) are large multimeric protein complexes that form hollow cylinders. They are 
constructed from repeats of a heterodimer of two 55 kDa proteins known as α and β tubulin. The 
formation of the tubulin dimer from the α /β monomers is essentially irreversible, locking a single 
molecule of GTP within the non-exchangeable nucleotide binding site of α tubulin (Weisenberg 
et al. 1976). Following the formation of the tubulin dimer, an additional molecule of GTP binds the 
β-subunit and subsequent subunit addition then brings the exposed, nucleotide bound β-tubulin into 
contact with α-tubulin from a separate tubulin dimer (Figure 1). This results in the formation of long 
chains of tubulin dimers known as protoﬁ  laments. This interaction at the α/β tubulin interface, within 
the growing protoﬁ  laments, promotes the hydrolysis of bound GTP, providing the conformational 
ﬂ  exibility required during the polymerization-depolymerization cycle (Wang and Nogales, 2005). In 
vitro, these ﬁ  laments have been shown to associate laterally, forming sheets which are then thought 
to curl in on themselves to form a complete MT. MTs observed in vitro are composed of 11 to 18 
individual protoﬁ  laments, whereas most microtubules that are observed in vivo are made up of only 
13 (Unger et al. 1990). MTs are involved in numerous critical, cellular processes including mitosis, 
cellular motility, maintenance of cellular morphology, and the activity of cell surface receptors. 
(Pichichero and Avers, 1973; Hyams and Stebbings, 1979). Here we discuss the role of MT dynamics 
and how tubulin’s involvement at the molecular level may affect processes such as chromosome 
segregation and cell division. This will be followed by a brief discussion of how this process relates 
directly to the chemotherapeutic treatment of cancer and the drugs that are used in this process. 
Finally, a discussion of the development of resistance mechanisms to these drugs and how these relate 
to tubulin, the expression of isotypes and acquired mutations will hopefully provide insight into the 
ever-increasing complexity of this system.Cancer Informatics 2007:3 160
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Tubulin structures
Several crystallographic structures of tubulin as it 
is found within several MT-like conformations are 
now available from the RCSB Protein Data Bank 
(PDB) (Nogales et al. 1995; Li et al. 2002; Wang 
and Nogales, 2005). The ﬁ  rst tubulin structure, 
1TUB, was crystallized as a ﬂ  at Zn
2+ induced sheet 
of antiparallel protoﬁ  lament-like end-to-end α /β 
dimer repeats, using docetaxel as a stabilizing 
agent (Nogales et al. 1998). Due to difﬁ  culties in 
ﬁ  tting electron density, this structure contains 
misalignments and was superseded by 1JFF, in 
which paclitaxel was utilized as a stabilizing agent 
(Lowe et al. 2001). Similarly, a third structure 
1TVK uses epothilone A, which binds at the same 
taxane binding site, stabilizing the MTs (Nettles 
et al. 2004). Additional structures use a stathmin-
like domain to produce crystals, the earliest, 1FFX, 
was derived from the 1TUB data (Gigant et al. 
2000). Two higher resolution structures, 1SA0 and 
1SA1 followed, producing structures of the colchi-
cine and podophyllotoxin bound complexes 
(Ravelli et al. 2004), while both the colchicine and 
vinblastine binding sites are observed in 1Z2B 
(Gigant et al. 2005). Structurally, α and β tubulin 
are known to be similar, indistinguishable at a 
resolution of 6 Å, yet share only 40% amino acid 
identity (Li et al. 2002). Each tubulin monomer 
can be divided into three distinct domains. The 
amino terminal domain (composed of residues 
1–205), an intermediate domain (residues 206–
381) and a carboxy terminal domain, which 
contains the flexible C-terminal tail (residues 
382–444). Unfortunately, while there is a wealth 
Figure 1. Paclitaxel, colchicine and Vinca binding sites on α /β tubulin protoﬁ  lament. Shown here is a cartoon representation of a protoﬁ  la-
ment with superimposed drug molecules, shown as space ﬁ  lling spheres. Structures of the paclitaxel (PTX), colchicine (CN) and vinblastine 
(VLB) from structural ﬁ  les 1JFF, 1SA0 and 1Z2B have been superimposed and ﬁ  t back onto the 1SA0 structure to obtain the relative posi-
tioning of each drug within the protoﬁ  lament. A single α /β-tubulin heterodimer comprises the β tubulin monomer (cyan) in the center of the 
frame and two α tubulin monomers (yellow) at the top and bottom of the frame. The GTP at the non-exchangeable and GDP at the exchange-
able site are colored purple.
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of information on the structure of tubulin, little is 
known about the functional signiﬁ  cance related to 
its structural features. This is almost entirely due 
to the lack of molecular understanding of the 
dynamic properties of tubulin dimers and how they 
behave within microtubules.
Microtubule structure and dynamics 
and the effect of drug interactions
MTs exhibit an irregular temporal pattern of 
assembly and disassembly, which has been termed 
dynamic instability (Mitchison and Kirschner, 
1984). The process of dynamic instability features 
episodes of distinct catastrophes that result in MT 
collapse, and rescues that lead to microtubule re-
growth (Bayley et al. 1990; Drechsel et al. 1992; 
Odde et al. 1995). The assembly and disassembly 
processes of MTs, both in vivo and in vitro, have 
been extensively studied and are regulated by 
mechanisms that are sensitive to temperature, pH 
and ionic concentrations that can accommodate the 
critical roles played by MTs at different phases of 
the cell cycle. Following the initial nucleation of 
a MT, the addition of subsequent tubulin dimers 
can occur at either of its free ends. Both polymer-
ized and unpolymerized tubulin monomers can 
bind free GTP, and upon assembly, the energy of 
hydrolysis from GTP to GDP is imparted into the 
tubulin subunits, however the outcome of this 
process and the fate of the energy released is yet 
unknown. It has been hypothesized that when β-
tubulin becomes bound within a MT, the exchange 
of bound GDP for GTP is blocked, and as a result, 
the protoﬁ  lament maintains its structure as long as 
there is not an exposed β-tubulin at the growing 
end. Stabilization of the entire MT structure is 
normally afforded by the binding of a GTP cap at 
the end of the MT which shields the terminal β 
tubulin from a conformational change that is then 
thought to induce its dissociation (Mitchison and 
Kirschner, 1984). We believe that at least part of 
the relatively large amount of energy is stored 
within the MT itself in the form of potential confor-
mational energy. When a critical amount of this 
potential energy has been exceeded, it is released 
in the form of a catastrophic collapse of the entire 
MT structure. 
The dynamic properties of MTs are especially 
critical during mitosis, when a delicate equilibrium 
of distances and forces is necessary for proper 
chromosome alignment prior to segregation 
(Margolis and Wilson, 1981; Horio and Hotani, 
1986; Melki et al. 1989; Walker et al. 1991; 
Mandelkow and Mandelkow, 1992; Zheng et al. 
1995). MTs comprise much of the mitotic spindle 
apparatus and its proper assembly is essential, as 
it likely provides the substantial mechanical force 
for mitotic chromosome segregation (Westermann 
et al. 2006). Assembly failure of the mitotic spindle 
generally results in mitotic arrest, apoptosis, and 
eventually cell death. As such, MTs have become 
the target for a large number of anti-mitotic agents 
including antitumor drugs such as the taxanes, 
epothilones, colchicine and Vinca alkaloids, 
including vinblastine and vincristine (Jordan and 
Wilson, 2004).
The method of action of these drugs is to either 
promote or inhibit MT polymerization by binding 
at specific sites on the surface of α/β-tubulin 
heterodimers (Figure 1). Paclitaxel, which 
continues to be one of the most successful cancer 
therapeutic agents, has a unique mechanism of 
action as it binds to and results in the stabilization 
of MTs within all cells (Wani et al. 1971; Schiff 
and Horwitz, 1980). Derivatives of paclitaxel, such 
as docetaxel, have been synthesized to address the 
limited solubility of paclitaxel and show increased 
binding to β-tubulin (Ringel and Horwitz, 1991). 
Two additional families of similar tubulin-binding 
drugs are the epothilones and dolastatins, which 
share a similar mode of binding. Interest in the 
epothilones over existing MT stabilizing agents 
such as paclitaxel is primarily due to their ability 
to retain cytotoxicity in multidrug resistant (MDR) 
cells (Bollag et al. 1995). Compounds, such as 
discodermolide and sarcodictyin have been shown 
to inhibit the proliferation of human cells through 
a mechanism similar do that of the taxanes. These 
compounds seem to selectively stabilize MTs 
during cell division, and outcompete paclitaxel for 
tubulin binding (Klein et al. 2005). In the absence 
of paclitaxel, it has been predicted that the energy 
stored in longitudinal contacts is greater than that 
stored in lateral contacts (VanBuren et al. 2002). 
Recent results using hydrogen/deuterium exchange 
coupled with mass liquid chromatography 
have demonstrated that increased rigidity in 
paclitaxel stabilized MTs was distinct from stabi-
lization as a result of GTP-induced polymerization 
(Xiao et al. 2006). The authors suggest that pacli-
taxel increases the overall energy associated with 
polymerization while maintaining the same differ-
ential between lateral and longitudinal contacts in Cancer Informatics 2007:3 162
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the microtubule lattice. Through structural studies 
both the taxanes and epothilones were shown to 
bind a unique site within the β subunit of the α /β-
tubulin heterodimer (Lowe et al. 2001; Nettles et 
al. 2004). Unfortunately, neither of the structures 
has been able to reveal the precise mechanism of 
MT stabilization by these drugs.
The Vinca alkaloids include vincristine vinblas-
tine and vinorelbine and are used most commonly 
in combination chemotherapy regimes. Vinblas-
tine was shown to bind at the inter-tubulin dimer 
interface, ultimately resulting in the net reduction 
of polymerized tubulin concentration (Gigant 
et al. 2005). At high concentrations the Vinca 
alkaloid, vinblastine, binds to MTs and results in 
their depolymerization. However, at low concen-
trations, vinblastine is thought to bind to MT tips 
and suppresses their dynamic instability, leading 
to stabilization (Toso et al. 1993). We feel that this 
may be a result of vinblastine’s ability to maintain 
the tubulin dimer at the end of the growing MT in 
a slightly bent conformation (Wang and Nogales, 
2005). If the tip of a protoﬁ  lament was maintained 
with a slightly bent conformation, due to the posi-
tioning of vinblastine between the dimers, then at 
low enough concentrations, a small amount of 
drug bound to the end of the MT would mimic the 
presence of a GTP cap, thereby resulting in MT 
stabilization.
The third observed drug site within β-tubulin 
was shown to bind colchicine, a water-soluble 
alkaloid that, like paclitaxel, binds to α /β tubulin 
dimers and blocks cell division thereby inhibiting 
mitosis (Ravelli et al. 2004). Unlike paclitaxel or 
vinblastine at low concentration, the binding of 
colchicine does not result in MT stabilization, but 
instead results in their destabilization since colchi-
cine binds only to free tubulin and not to tubulin 
polymerized into MTs.
Following exposure to all of these drugs, cells 
experience mitotic arrest, which eventually leads 
to apoptosis. This makes these drugs extremely 
effective chemotherapeutic agents’ for targeting 
all rapidly dividing cancerous cells. Nevertheless, 
even the most successful chemotherapy drugs have 
undesirable side effects that limit their utility. The 
anti-tubulin chemotherapeutic agents’ main ﬂ  aw 
is that they bind tubulin indiscriminately, leading 
to the widespread destruction of both cancerous 
and healthy cells, resulting in unwanted side-
effects such as neuropathy (Rowinsky et al. 1989). 
The ultimate goal of chemotherapy research is to 
develop a drug or treatment regimen that will target 
only cancer cells and will target them selectively. 
In the case of paclitaxel, this would require deter-
mining the differences between tubulin as observed 
in cancerous cells and non-cancerous cells. Fortu-
nately there are slight differences within several 
β-tubulin isotypes expressed in a range of cell types 
that may afford a foundation for the development 
of anti-tubulin drug derivatives with increased 
speciﬁ  city for particular cancer cells. Unfortu-
nately, as the precise binding modes of these 
compounds within β-tubulin is not yet able to fully 
explain how these drugs affect MT stabilization, 
our ability to create a precise molecular model of 
their effects is limited.
Tubulin isotypes
Many eukaryotic organisms carry multiple 
genomic copies of functional α or β tubulin, 
commonly referred to as isoforms (or isotypes if 
they are conﬁ  ned to a single organism). At the 
cellular level, the role of tubulin is extremely 
complex and seems to be related to subtle struc-
tural variations observed between the α and β 
isoforms (Richards et al. 2000). For instance, MT 
dynamics appears to change signiﬁ  cantly as a 
function of β tubulin isotype expression (Panda 
et al. 1994). This result implies that if MT assembly/
disassembly equilibrium is disrupted through some 
external stimulus, cells could respond by producing 
an appropriate isotype mix to restore normal 
balance. The existence and varied distribution of 
tubulin isoforms provides a link to their function in 
the polymerization and stability of MTs. While the 
presence of numerous tubulin isoforms suggests that 
they may play speciﬁ  c roles in MT function, there 
are no precise predictive models to describe differ-
ences between them.
In humans, several α and β tubulin isotypes have 
been identiﬁ  ed and characterized (Lu and Luduena, 
1994; Luduena, 1998; Roach et al. 1998). While α 
tubulin must play an obvious role in the determination 
of MT function, we have chosen to focus only on β 
tubulin for this discussion, as most of the available 
data in the literature deals with this protein as a target 
for drug action and protein-protein interactions. 
Through a search of available protein sequence data-
bases, we have previously identiﬁ  ed a total of ten 
unique β tubulin isotypes, all of which have related 
amino acid sequences and are generally well 
conserved (Huzil et al. 2006). Despite having similar Cancer Informatics 2007:3 163
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Figure 2. Sequence alignment of β tubulin isoforms. Each of the ten Human β-tubulin isoforms that was identiﬁ  ed in our screen of the Uni-
prot and NCBI Entrez databases was aligned using the ClustalW software package (Thompson et al. 1994). Prior to performing the alignment, 
the highly variable carboxy terminal residues were removed from each sequence. This was done as the structural ﬁ  le, 1JFF, does not con-
tain any of these residues. At each position within the alignment, black boxes indicate identical residues, grey boxes indicate residues that 
are conserved, while white boxes indicate residues that are divergent. The 6 Å cutoff binding sites for paclitaxel, colchicine and vinblastine 
are indicated by boxes labeled PTX, CN and VLB, respectively.Cancer Informatics 2007:3 164
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sequences, speciﬁ  c regions of higher sequence vari-
ability have been identified (Figure 2). The highest 
degree of sequence variability between the α and 
β-tubulin isotypes occurs in the extreme carboxy 
terminal region (residue 430 and greater). This 
C-terminal region has been used to identify distinct 
β-tubulin isotypes, based on their reactivity with 
monoclonal antibodies (Banerjee et al. 1990; Panda 
et al. 1994).
Each β-tubulin isotype seemingly has a unique 
pattern of expression ranging from highly speciﬁ  c 
for classes III, IVa and VI, to constitutive expres-
sion for classes I and IV (Cowan and Dudley, 1983; 
Jensen-Smith et al. 2003). Class I β-tubulin is the 
most commonly expressed isotype in humans and 
as such is also the most common isotype found in 
cancer cells (Sullivan and Cleveland, 1986). Both 
classes II and III β-tubulin have been observed at 
increased levels in human tumors (Scott et al. 1990; 
Ranganathan et al. 1996; Kavallaris et al. 1997; 
Prasannan et al. 2000; Dozier et al. 2003; Ferguson 
et al. 2005; Mozzetti et al. 2005).
Recently, the role of β-tubulin isotypes in resis-
tance to anti-mitotic drugs has become a topic of 
great interest, as the design of novel drugs based 
on isotype speciﬁ  c differences would result in 
better treatment protocols (Burkhart et al. 2001). 
However, in addition to functional tubulin 
isotypes, the tubulin gene family also contains 
several pseudo-genes, which are non-functional 
sequences within the genome having close simi-
larities to functional genes. There are several 
human β-tubulin pseudo-genes, all of which show 
substantial homology to the Class I β-tubulin gene, 
a situation which has resulted in the erroneous 
identiﬁ  cation of several tubulin mutations that 
correlate with paclitaxel resistance (reviewed by 
Berrieman et al. 2004). This has added controversy 
to an otherwise attractive hypothesis that muta-
tions within the β-tubulin genes can lead to drug 
resistance.
Drug resistance mechanisms 
involving tubulin
As with all chemotherapeutic treatments, the devel-
opment of drug resistance to anti-tubulin agents is 
a major clinical problem with no simple solution. 
Drug resistance can originate through several 
mechanisms involving: (a) changes in cellular drug 
uptake, (b) drug metabolism, (c) structural changes 
in the drug target, (e) drug efﬂ  ux, or (f ) changes 
in cellular components that interact with the target. 
Cell culture studies have previously demonstrated 
that the most frequent mechanism for resistance to 
drugs such as the colcemides and Vinca alkaloids 
is P-glycoprotein mediated multidrug resistance 
(Cabral and Barlow, 1989; Dumontet et al. 1996). 
However, in direct contrast to this observation, 
cells which show resistance to taxanes tend to 
exhibit alterations in tubulin expression patterns 
with low P-glycoprotein activity. In addition to the 
altered expression of β-tubulin isotypes, point 
mutations in tubulin leading to alterations and 
expression related post-translational modiﬁ  cations 
of tubulin regulatory proteins, such as stathmin, 
microtubule associated protein (MAP), tau and 
MAP4 have also been implicated in changes to MT 
dynamics and the development of drug resistance 
(Liu et al. 2001).
In addition to isotype expression and acquired 
mutations, tubulin is also thought to undergo an 
auto-regulatory mechanism where treatment with 
MT destabilizing drugs, such as colchicine, will 
ultimately result in the coordinated degradation of 
tubulin mRNA and a corresponding reduction of 
cellular free tubulin dimers. The synthesis of α and 
β-tubulin monomers appears to be regulated by a 
mechanism in which α-tubulin translation is inhib-
ited by free α-tubulin but not by α-tubulin that is 
complexed with the β-subunit (Gonzalez-Garay 
and Cabral, 1996). In this way, β-tubulin is synthe-
sized only when there are available α-subunits to 
which it can bind. The treatment of cells with MT 
stabilizing drugs, such as paclitaxel results in the 
overall stabilization of tubulin mRNA and an 
increase in tubulin protein due to a net reduction 
in concentration directly following drug treatment. 
This results in the overall equilibrium of free 
tubulin within the cell and maintains a steady 
supply of tubulin for MT synthesis (Boggs and 
Cabral, 1987; Theodorakis and Cleveland, 1992; 
Barlow et al. 2002). This further implies that any 
mutation or expression of a tubulin isotype that 
affects the overall stability of MTs will also have 
an effect on the total amount of free tubulin dimers 
that are present within the cell.
Finally, tubulin can also be controlled post-
translationally through degradation. Although 
tubulin heterodimers are very stable (Spiegelman 
et al. 1977), excess free subunits (Gonzalez-Garay 
and Cabral, 1995) or defective tubulin proteins 
have a much shorter half-life (Kemphues et al. 
1982; Boggs and Cabral, 1987). The tubulin Cancer Informatics 2007:3 165
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molecule is also subject to several post-transla-
tional modiﬁ  cations which are thought to also 
affect their rate of assembly into MTs. Some of 
these modiﬁ  cations, such as phosphorylation and 
acetylation are common to many proteins. Others, 
such as polyglutamylation, are very rare, while still 
others, such as tyrosinolation/detyrosinolation and 
polyglycylation, have so far been reported only in 
tubulin (Luduena, 1998; MacRae, 1997; Wester-
mann and Weber, 2003; Soucek et al. 2006).
Drug resistance due to β-tubulin
isotype expression levels
Several studies have pointed to the over-expression 
of tubulin isotypes as a possible mechanism 
resulting in drug resistance ( Banerjee et al. 1990; 
Minotti et al. 1991; Banerjee and Luduena, 1992; 
Haber et al. 1995; Kavallaris et al. 1997; Derry 
et al. 1997; Banerjee and Kasmala, 1998; Ranga-
nathan et al. 1998; Verdier-Pinard et al. 2003). 
While other studies suggest that expression of 
certain tubulin isotypes does not lead to paclitaxel 
resistance (Blade et al. 1999; Nicoletti et al. 2001; 
Sale et al. 2002). However, as more data is 
acquired, it is becoming clear that isotype expres-
sion does lead to drug resistance at some level. In 
particular, Class III β-tubulin has been implicated 
in paclitaxel resistance through a mechanism that 
results in decreased MT stability, thus counter-
acting the effect of paclitaxel (Sangrajrang et al. 
1998; Katsetos et al. 2003; Hari et al. 2003a; Shalli 
et al. 2005). More speciﬁ  cally it appears that the 
expression of speciﬁ  c tubulin isotypes, such as 
βIII, may not affect MT dynamic instability in the 
absence of drugs such as paclitaxel, but may act to 
suppress the drug’s ability to affect MT dynamics 
directly (Kamath et al. 2005). Finally, support for 
the role of tubulin isotype expression and their 
effect on drug resistance was observed when anti-
sense oligonuclotides speciﬁ  c for βIII result in the 
resensitization of resistant cells to paclitaxel 
(Kavallaris et al. 1999). In addition to the several 
observations of tubulin isotype expression patterns 
in tumor cells, the expression of tubulin isotypes 
has also been implicated in the differentiation state 
of cells (Carles et al. 1999).
We have previously described the construction 
of a complete set of homology models for the 
human β-tubulin isotypes and described several 
differences that we observed between them (Huzil 
et al. 2006). Sequence alignment of all the β-tubulin 
isotypes demonstrates that many of the differences 
between them occur outside the main drug binding 
sites (Figure 2). When displayed on the surface of 
the 3D tubulin structure, it becomes apparent that 
most of the differences found between the various 
isotypes are restricted to the lateral and longitudinal 
surfaces that are involved in protein-protein inter-
actions with the neighboring tubulin dimers in the 
MT (Figure 3). Differences at these locations may 
provide the cell with the ability to alter expression 
patterns for tubulin isotypes and in this way affect 
the overall kinetics of MT assembly and disas-
sembly. This could be in response to such external 
stimuli as temperature changes or drug exposure. 
Interestingly, several differences can be observed 
on the exterior face of the β-tubulin when it is 
assembled into the MT, while there are signiﬁ  cantly 
fewer observed differences on the inner surface. 
This may be a result of selective differences 
between isotypes that are meant to accommodate 
Microtubule Associated Protein (MAP) binding, 
thereby leading to altered MT kinetics (Kurz and 
Williams, 1995).
The underlying molecular mechanisms of 
tubulin isotype expression, in particular Class III 
β-tubulin over-expression, in drug resistance are 
not well understood. There are a number of possi-
bilities, including tubulin’s normal vibrational 
modes, perhaps resulting in altered protein 
dynamics. More likely, it is a critical change 
within surfaces that interact during MT assembly. 
Therefore, the expression of specific tubulin 
isotypes could result in the alteration of MT 
stability. A cellular requirement for less stable 
MTs may then result in the over-expression of 
isotypes such as βIII, which has been demon-
strated to be produce more dynamic MTs than 
other isotypes (Derry et al. 1997).
Tubulin mutations 
and drug resistance
The ﬁ  rst studies that identiﬁ  ed resistance to anti-
mitotic drugs through a mechanism of β tubulin 
mutation were originally performed in the early 
1980’s (Ling et al. 1979; Cabral et al. 1980; 
Keates et al. 1981; Cabral et al. 1982; Cabral and 
Barlow, 1989). However, the work of Monzo 
et al. (1999) in observing mutations of β-tubulin 
in human lung cancer cell lines has been the 
source of much controversy since its publication. 
It has since been suggested that the presence of Cancer Informatics 2007:3 166
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Figure 3. Surface map of nonconserved residues in all Human β-tubulin isoforms. A solvent accessible surface was drawn onto the α /β-
tubulin heterodimer obtained by Nogales et al. 2001 (PDB identiﬁ  er 1JFF). This ﬁ  gure shows an α /β-tubulin heterodimer within a MT contain-
ing 13 protoﬁ  laments which was reconstructed as described by Li et al. (2002). The α-tubulin surface is colored yellow and the β-tubulin 
surface colored cyan with nonconserved positions colored red. Panel A. Illustrates the MT from the interior surface and shows the binding 
site for paclitaxel (purple). Panel B. Illustrates a 180° rotation about the y-axis to show the exterior surface of the microtubule.
B. β-Tubuiln Isotypes MT Exterior
A. β-Tubuiln Isotypes MT InteriorCancer Informatics 2007:3 167
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tubulin pseudo-genes and sequencing errors result 
in erroneous interpretation and therefore makes 
determining true mutations in tubulin difﬁ  cult. 
Many sequencing errors within the β-tubulin gene 
tend to be a result of primer selection where 
intronic primers are used or pseudo-genes are 
inadvertently sequenced (de Hasegawa et al. 
2002; Tsurutani et al. 2002; de Castro et al. 2003; 
Achiwa et al. 2003; Maeno et al. 2003; Berrieman 
et al. 2004; Mesquita et al. 2005).
It has been suggested that differences in drug 
binding afﬁ  nities do not play a signiﬁ  cant role for 
the colcimides or vinblastine with regards to the 
acquisition of tubulin mutations in certain cell lines 
(Hari et al. 2003b). However, there are several 
studies, discussed below, that point to a role for 
mutations within the taxane binding site as a 
mechanism for resistance to paclitaxel. We feel that 
mutations observed within the β-tubulin genes may 
not result in changes to drug binding afﬁ  nity, but 
will more likely play a role at distant locations 
within the protein. The rarity of true somatic muta-
tions in tubulin in clinical samples also suggests 
that other mechanisms, such as drug efﬂ  ux or 
changes in the expression levels of the different 
β-tubulin isotypes, are a more important contrib-
uting factor for anti-tubulin drug resistance (de 
Castro et al. 2003; Maeno et al. 2003; Hasegawa 
et al. 2002; Ferguson et al. 2005). However, the 
positive data obtained with cell lines suggests that 
further investigation is needed to ascertain what 
role, if any, mutations in the β-tubulin gene have 
in predicting clinical response to anti-tubulin 
agents. We cannot discount the role of intronic 
mutations and their observed role for drug resis-
tance and how this may ultimately affect gene 
expression of a particular tubulin isotype as de 
Castro et al. (2003) observed that as alterations in 
β-tubulin were ampliﬁ  ed with exonic primers less 
clinical response to paclitaxel was observed. Addi-
tionally, observations made with regards to 
acquired mutations are often complicated by the 
concurrent overexpression of different tubulin 
isotypes, making the interpretation of results 
difﬁ  cult.
Analysis of Speciﬁ  c β-Tubulin 
Mutations
To determine which residues within each of previ-
ously described drug binding sites within β-tubulin 
are essential for activity, we examined the location 
of reported mutations that confer resistance to 
tubulin-binding drugs in all reported mammalian 
cells (Table 1). There seemingly is little correlation 
between the overall structure of the paclitaxel 
binding site and the location of mutations in β-
tubulin that occur as a result of resistance following 
exposure to paclitaxel (Figure 4). We have observed 
that within the set of 21 unique positions within 
the tubulin sequence, only eleven mutations were 
found to be contained within the taxane binding 
site (Figure 5a). Only eight of these substitutions 
were identiﬁ  ed as becoming either paclitaxel or 
epothilone resistant. Interestingly three of the 
mutations within the taxane binding site resulted 
in MT stabilization and as a result became resistant 
to either colchicine or vinblastine. Of the remaining 
ten sites within β-tubulin, ﬁ  ve were shown to 
become paclitaxel resistant, yet did not occur in 
the vicinity of the taxane binding site (Figure 5b). 
Of two sites found near the colchicine binding site, 
only K350N was identiﬁ  ed as being colchicine 
resistant (Figure 6a) (Hari et al. 2003b). Interest-
ingly, mutation L240I, which is also found near 
the colchicine binding site, confers resistance to 
vinblastine (Kavallaris et al. 2001). This was a 
remarkable observation as the Vinca binding site 
is on the opposite face of β-tubulin from the colchi-
cine binding site (Figure 1). There are also two 
mutations situated near the Vinca binding site. The 
first at S172 conferred vinblastine resistance 
(Poruchynsky et al. 2004) and the second, at P173 
curiously conferred epothilone resistance with an 
opposing MT destabilizing phenotype (Figure 6b) 
(He et al. 2001).
Mutations found within the taxane 
binding site
When examining mutations acquired following 
exposure to taxanes or epothilones, several are 
found directly within the taxane binding site and 
could therefore affect drug binding through VDW   
(Van der Waals (VDW) interactions, electrostatics 
or hydrophobic differences. These include C211, 
L215, L217, D224, L228, A231, S234, F270, T274 
and R282 A364 (Figure 5a). We should note that 
while all of these residues are located within close 
proximity of the bound paclitaxel molecule from 
the 1JFF structure, most were reported not to 
change the afﬁ  nity of the taxanes or epothilones, 
but appear to destabilize MTs in the absence of any 
drug (Gonzalez-Garay et al. 1999; Verrills et al. Cancer Informatics 2007:3 168
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Table 1. Observed β tubulin mutations in mammalian cell lines as a result of acquired drug resistance. The 
columns representing drug interactions indicate residues in which any atom is within 6 Å of any atom within the 
bound drug molecule from structural ﬁ  les 1JFF, 1SA0 and 1Z2B for Paclitaxel (PTX), Colchicine (CN) and Vin-
blastine (VLB) respectively.
                                                        Drug Interactions
Mutation Cell  Type  Reference  Phenotype  PTX  CN  VLB
 D45Y  CHO  Barlow 2002, Hari  Increased MT stabilization
       2003, Wang 2004  Growth dependent on Colchicine         
 V60A,F  CHO  Wang 2004, Yang 2005  Decreased MT stabilization
            Taxol resistant Cis-acting suppressor 
           of D45Y         
S172A  Human  Poruchynski 2004  Increased MT stabilization     
            Hemiasterlin Colchicine and      *  
            Vinca resistance.
                     
P173A  CHO  He 2001  Decreased MT stabilization     
            Epothilone A resistant.        *
D197N  Human  Gokmen 2005  Increased MT stabilization
            2-Methoxyestradiol and Vinca
            resistant. No effect on Taxol 
           or Colchicine phenotype         
 C211F  CHO  Hari 2004  Increased MT stability
            Colchicine and vinca  *     
            resistance         
 L215*  CHO  Gonzales 1999, Barlow   Decreased MT stabilization
       2002, Wang 2006  Taxol resistance.  *
           Not implicated in drug binding         
 L215V  CHO   Wang 2006  Normal Phenotype  *     
 L215I  CHO  Wang 2006  Decreased MT stabilization          
           Taxol sensitivity, but not  *     
           Epothilone Sensitive         
 L217R  CHO  Gonzales 1999  Decreased MT stabilization
            Taxol resistant. Not implicated  *
            in drug binding        
 D224N  CHO  Hari 2003  Increased MT stability
           Colchicine and vinca resistance  *     
 L228F,R  CHO  Gonzales 1999  Decreased MT stabilization
            Taxol resistance. Not  *
           implicated in drug binding        
 A231T  Human  Verrills 2003  Decreased MT stabilization
            Taxol resistant, hypersensitive  *
            to destabilizing compounds        
 S234N  CHO  Hari 2003  Increased MT stability
           Colchicine and vinca resistance  *     
 L240I  Human  Kavallaris  Increased MT stabilization
            Vinca and Colchicine resistant     *   
ContinuedCancer Informatics 2007:3 169
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F270V  Human  Giannakakou 1997  Decreased MT stabilization
          Taxol resistance  *      
T274I  Human  Giannakakou 2000  Decreased MT stabilization
          Epothilone resistant reduced
           sensitivity to Taxol may  *
          affect drug binding        
R282N  Human  Giannakakou 2000  Decreased MT stabilization
          Epothilone resistant reduced
          sensitivity to Taxol may   *
          affect drug binding     
Q292H,E  CHO  He 2001, Verrills 2003,  Decreased MT stabilization
   Human  Wang 2004, Yang 2005  Taxol resistant Cis-acting
          suppressor of D45Y         
R306C  Human  Hasegawa 2002  Not known how this confers
           PTX resistance
          only a genetic study         
K350N  Human  Hari 2003,Gokmen   Increased MT stabilization
      2005  2-Methoxyestradiol and vinca
          resistant. No effect on Taxol    *
          or Colchicine phenotype        
A364T  Human  Giannakakou 1997  Decreased MT stabilization
           PTX resistance  *     
Y442C  CHO  He 2001  Decreased MT stabilization
           Epothilone A resistant
                                                        Drug Interactions
Mutation Cell  Type  Reference  Phenotype  PTX  CN  VLB
2003; Hari et al. 2003b). Of these eleven residues 
found to be directly in contact with either paclitaxel 
or epothilone, only F270V, T274I and R282N were 
reported to have a direct effect on drug binding 
afﬁ  nity (Giannakakou et al. 1997; Giannakakou et 
al. 2000). This observation suggests that there must 
be a global effect on tubulin dimer interactions that 
are involved in MT assembly rather than a reduced 
paclitaxel binding effect as the mechanism for drug 
resistance.
C211/D224/S234. Substitutions at C211, D224 
and S234 all were all shown to result in resistance 
to both colchicine and vinblastine, producing an 
increase in MT stability and the amount of polym-
erized MT observed within cells (Hari et al. 2003b). 
All of these substitutions are located within a 
structure known as the M loop, which has been 
shown to be critical for the function of paclitaxel 
and MT dynamics, affecting lateral interactions 
between tubulin subunits in the MT (Figure 5a) 
(Keskin et al. 2002). The signiﬁ  cance of this region 
in MT assembly is illustrated, not only by the fact 
that both the paclitaxel and colchicine binding sites 
are nearby, but also because many mutations 
conferring resistance to drugs that either promote 
or inhibit MT assembly are also located in this 
same area (see following discussion). This is an 
interesting result, as these residues are clearly 
located near the taxane binding site and are within 
8–10 Å of bound paclitaxel. However, their prox-
imity to both the GTP binding site and the colchi-
cine binding site may also result in alternate 
phenotypes depending on the substitutions. This 
is supported by the observation that mutations at 
these positions in yeast were shown to confer vari-
able drug resistance depending on the amino acid 
substitution indicating the critical role that this 
region plays in MT stability and drug resistance 
(Gupta et al. 2001).
L215, L217, L228. Analysis of β-tubulin alleles 
from nine paclitaxel-resistant Chinese Hamster 
Ovary (CHO) cell lines revealed a cluster of muta-
tions affecting L215, L217, and L228 (Gonzalez-
Garay et al. 1999). At position 215, histidine, Cancer Informatics 2007:3 170
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Figure 4. Surface map of mutation sites in mammalian β-tubulin. As in Figure 3, a solvent accessible surface was drawn onto the α /β-tubu-
lin heterodimer and assembled into a 13 protoﬁ  lament MT. Here the β-tubulin surface is colored red to illustrate the surface positions of 
mutations observed in Table 1. Panel A. Illustrates the MT from the interior surface and shows the binding site for paclitaxel (purple). 
Panel B. Illustrates a 180° rotation about the y-axis to show the exterior surface of the microtubule.
B. β-Tubuiln Mutations MT Exterior
A. β-Tubuiln Mutations MT ExteriorCancer Informatics 2007:3 171
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Figure 5. Location of mutations in mammalian β-tubulin in the taxane binding site. As in Figure 3, with the exception that the β-Tubulin surface 
has been removed to expose the underlying tertiary structure which is shown as a cyan cartoon. Panel A. Shows mutations found within the 
taxane Binding Site (C211, L215, L217, D224, L228, A231, S234, T274, F270, R282, S364) colored red in relation to paclitaxel (purple). 
Panel B. Shows residues found outside the taxane binding site (E45, V60, Q292, R306) colored red. Residues found within the Vinca binding 
site (S172 and P173) are colored yellow and residues found within the colchicine binding site (L240 and K350) are colored orange.
B. β-Tubuiln Mutations Not In PTX Site
A. β-Tubuiln Mutations Within PTX SiteCancer Informatics 2007:3 172
Huzil et al
Figure 6. Location of mutations in mammalian β-tubulin in the colchicine and Vinca binding sites. As in ﬁ  gure 5, the surface has been removed 
from β-tubulin. Panel A. Shows a view of the colchicine binding site from the longitudinal surface between an α /β-tubulin heterodimer. The 
α-tubulin has been removed to facilitate viewing of the bound colchicine within the β-tubulin a second α-tubulin can be seen behind 
β-tubulin in the background. Colchicine is colored green and is shown as sticks. The two mutated residues (L240 and K350) are shown as 
red sticks. Panel B. Shows a view of the Vinca binding site from the lateral surface between two protoﬁ  laments. The vinca alkaloid vinblas-
tine is shown as green sticks and the two mutated residues (S174 and P175) are shown as red sticks.
B. Vinblastine Binding Site Lateral Surface
A. Colchicine Binding Site Longitudinal SurfaceCancer Informatics 2007:3 173
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arginine, or phenylalanine substitutions were 
observed, while at position L217, an arginine and 
at L228 either histidine or phenylalanine substitu-
tions were observed. All of these mutations resulted 
in a decrease in MT stability, as demonstrated by 
an overall reduction in the level of polymerized 
tubulin within the cell and by increased resistance 
to paclitaxel. Substitutions at positions L215 and 
L217 are in a loop that connects helices H6 and 
H7, while L228 is located within H7 itself 
(Figure 5a). These substitutions may produce 
resistance as a result of their location in or near H7 
since it has been hypothesized that H7 controls the 
conformation of the entire molecule (Amos and 
Lowe, 1999). An interesting observation was made 
by Wang et al. (2006) when the substitution L215V 
did not produce any observable phenotype while 
mutation to any other residue produced cells resis-
tant to paclitaxel as a result of global MT destabi-
lization. Perhaps the speciﬁ  c spatial arrangement 
of the two methyl groups found on leucine and 
valine results in no observable effect for this muta-
tion. However, this observation requires additional 
experimentation before a concrete mechanism can 
be established for this apparent selectivity.
T274/R282. In addition to describing a common 
pharmacophore for Epo A/Epo B binding which 
may explain mutational effects at L215, L217 and 
L228, Giannakakou et al. (2000) also identiﬁ  ed 
mutations at positions T274 and R282 as conferring 
either epothilone or paclitaxel resistance. Both of 
these mutations resulted in a similar reduction in 
the overall amount of polymerized tubulin within 
the cell. While these mutations did seem to have an 
effect on the ability of tubulin to bind either epothi-
lone or paclitaxel, they also conferred a greater 
degree of MT destabilization, which is most likely 
the major factor leading to drug resistance. Both of 
these residues are found within the M loop and their 
interactions with the taxane site are direct and most 
likely signiﬁ  cant (Figure 5a). As the amino terminus 
of the M loop comprises part of the taxane 
ring-binding region, a mutation of R282 could 
directly affect the binding of both the taxanes and 
epothilones. However, as previously discussed, 
the involvement of the M loop within longitudinal 
MT interactions is extremely important for proper 
assembly and stability. The importance of 
this region is further supported by the observation 
that both T274 and R282 are evolutionarily 
conserved in all known human β-tubulin isotypes 
(Figure 2).
The C4–C5 oxetane of the bound taxane is 
located near the polar backbone atoms of residues 
273, 275, 276 and the hydroxyl side chain of T274. 
Therefore, substitutions of this residue may lead 
to a change in the hydrophillicity of this region 
making taxane binding less favorable. Addition-
ally, Giannakakou et al. (2000) also hypothesized 
that cross-resistance to both epothilone and pacli-
taxel may be a result of the epothilone C7-OH 
hydrogen bond with the vicinity of T274. There-
fore, T274I results in the loss of this hydrogen 
bond. In contrast, paclitaxel has hydrogen bond 
donors or acceptors at their C10, C9, and C7 
positions and can presumably form alternate 
hydrogen bonding patterns.
F270V, A364T. Cell cultures resistant to pacli-
taxel but not epothilone and not dependent on 
paclitaxel for growth, suggested that the mutation 
F270V is speciﬁ  c only for paclitaxel binding and 
does not lead to an overall reduction in MT 
assembly kinetics (Giannakakou et al. 2000). 
However, collateral sensitivity to vinblastine 
suggests a global destabilization of the MT struc-
ture also. This mutation was independently selected 
along with another mutation, A364T, which also 
demonstrated the same paclitaxel, but not epothi-
lone-resistant phenotype. Both of these substitu-
tions occur within the taxane binding site and 
comprise the majority of the surface that makes up 
the ﬂ  oor of this binding site (Figure 5a). Several 
possible interactions with the taxane C13 side chain 
are possible. Substitution of A364T would result 
in a polar residue in this normally hydrophobic 
surface. While F270 does not seem to participate 
in any signiﬁ  cant ring interactions, this effect 
cannot be ruled out as it is in close proximity to 
both C13 phenyl rings. The resistance to paclitaxel 
but not epothilone for both of these substitutions 
suggests that there is a difference in the binding 
pocket that does not affect epothilone binding. This 
effect may be due to the epothilone molecule sitting 
higher within the binding pocket at this region 
and/or due to the lack of potential aromatic interac-
tions with F270.
A231. Through screening a series of desoxye-
pothilone B resistant leukemia cell lines, the muta-
tion A231T was seen to be producing less stable 
MTs (Verrills et al. 2003). This substitution was 
shown to confer resistance to the epothilone analog 
desoxyepothilone B, but did not seem to alter drug 
binding. The authors also observed that cells 
carrying this mutation were hypersensitive to Cancer Informatics 2007:3 174
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microtubule destabilizing agents and expressed 
increased levels of class III β-tubulin. These cells 
also characteristically had a greatly reduced tubulin 
polymer mass which is indicative of reduced MT 
stability. The A231T substitution is located on H7 
within the highly hydrophobic region of the taxane 
binding site (Figure 5a). Substitution of a hydro-
phobic alanine to a polar threonine residue should 
produce a significant effect on drug binding. 
However, as there was no observable effect on 
paclitaxel binding, the authors suggested that the 
change was more likely to result in the alteration of 
the conformation of the H7, thereby affecting MT 
stability through a reduction in the α helical propen-
sity associated with threonine over alanine.
Q292. Cells carrying a Q292E,H mutation were 
shown to become resistant to epothilone and 
paclitaxel probably as a result of reduced drug 
binding (He et al. 2001; Verrills et al. 2003; Yang 
et al. 2005). This mutation was originally identiﬁ  ed 
as a suppressor of the mutation D45Y, originally 
identiﬁ  ed by Wang et al. (2004). In the presence 
of the mutation A231T, which was not shown to 
affect paclitaxel binding directly, mutations at 
position 292 were shown to reduce paclitaxel 
binding (Verills et al. 2003). As both of these muta-
tions resulted in reduced MT levels, the mutation 
of residue 292 may have a direct inﬂ  uence on 
paclitaxel binding. Interrestingly, as can be seen 
in Figure 5a Q292 is not in direct contact with the 
bound paclitaxel molecule, but is located on H9 
near the M loop, which is implicated in the critical 
lateral contacts within the MT. This residue is also 
approximately 7.5 Å from the four-membered 
oxetane ring within paclitaxel or the ketone oxygen 
within epothilone and may therefore affect the 
binding pocket indirectly. Additionally, both gluta-
mine and glutamic acids prefer solvent exposed 
conformations, they are frequently observed at 
protein interfaces. The resulting change from 
glutamine to glutamic acid introduces a negative 
charge which may decrease protoﬁ  lament-proto-
ﬁ  lament interactions at this surface. This hypoth-
esis is supported by the observation that cells 
carrying this mutation are sensitive to treatment 
with MT destabilizing drugs such as vinblastine. 
When the Q292E was expressed in combination 
with V60P cells became dependent on epothilone 
for growth (Yang et al. 2005). Both mutations at 
Q292 and V60 would be expected to impact lateral 
contacts between protoﬁ  laments. Therefore, cells 
carrying these mutations would require MT stabi-
lizing drugs, such as paclitaxel or epothilone, to 
compensate for the increased instability of their 
MTs. Because of its close proximity to the taxane 
binding site, this mutation may have an effect on 
drug binding, although this is not likely.
Mutations within the colchcicine 
binding site
L240. The L240I mutation was identiﬁ  ed in tumor 
cell lines that became resistant to the MT desta-
bilizing drug vincristine as a result of increased 
MT stability (Kavallaris et al. 2001). This muta-
tion lies in a region of β-tubulin that is in close 
proximity to the α /β-tubulin interface on the loop 
that links H7 and H8 (residues 238–250) (Figure 6a). 
A mutation at this position would affect longitu-
dinal interactions between α and β monomers 
thereby stabilizing MTs conferring its observed 
vinca resistance phenotype. The authors proposed 
that a leucine-to-isoleucine substitution at this 
position is close to alanine 248 and may result in 
a conformational change within H7. As discussed 
previously, H7 lies at the base of the taxane 
binding site and has been implicated in the global 
stability of the tubulin dimer (Amos and Lowe, 
1999). This would support the observation that 
cells carrying this mutation also had a concurrent 
increase in polymerized tubulin. Due to its 
distance from the Vinca binding site, this mutation 
was hypothesized not to have an effect on drug 
binding, but is thought to lead only to increased 
MT stability.
D350. See the D197/K350 discussion below.
Mutations within the Vinca 
binding site
S172. A single mutation at position S172 resulted 
in an overall increase in MT stability and a 
resulting resistance to the hemiasterlin HTI-286 
(Poruchynsky et al. 2004). This mutation also 
produced cross-resistance to vinblastine binding 
site agents, as the hemiasterlins have been 
proposed to share a binding region on tubulin with 
the vinca alkaloids (Bai et al. 1999). This mutation 
was shown to affect polymerization through the 
stabilization of MT thereby producing resistance 
to destabilizing and sensitivity to polymerizing 
drugs. The main reasoning for this may be due to 
the fact that S172 has recently been shown to be 
a substrate for phosphorylation by cyclin-depen-Cancer Informatics 2007:3 175
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dent kinase Cdk1 at the transition from interphase 
to mitosis (Fourest-Lieuvin et al. 2006). The 
phosphorylation of this Serine residue was shown 
to decrease MT stability and its loss would effec-
tively stabilize MTs, thereby making them more 
resistant to destabilizing drugs. Therefore, resis-
tance may be due an increase in stability or may 
also be a result of reduced drug binding due to its 
proximity to the Vinca binding site. 
Interestingly, mutation of P173A has the oppo-
site effect leading to MT destabilization and resis-
tance to epothilone and sensitivity to colchicine 
(He et al. 2001). This difference may be due to a 
catastrophic conformational change in the T5 loop 
as a result of the loss of P173. Neither of these 
mutations was shown to have any effect on drug 
binding.
P173. Mutations at P172 were shown not to 
affect the binding of Epothilone and have a desta-
bilizing effect on MT structure in HeLa cells (He 
et al. 2001). P173 is located on the T5 loop which, 
as just described, is involved in forming the ribose 
binding component of the nucleotide binding 
pocket (Figure 6b). It is highly probable that P173 
acts to stabilize this loop and is, therefore, essential 
for proper nucleotide orientation within the nucle-
otide binding pocket. This would then have a direct 
effect on nucleotide binding and subsequent hydro-
lysis, resulting in altered MT dynamics. Interest-
ingly, while this mutation occurs next to S172, it 
has the completely opposite effect, resulting in the 
destabilization of MTs and a resistance to MT 
stabilizing drugs.
Mutations outside the drug 
binding sites
D45. The mutant D45Y was shown to confer 
growth dependence on colcemid as a result of MT 
stabilization (Wang et al. 2004). This mutation 
caused an increase in the levels of polymerized 
tubuiln found within the cell, supporting the stabi-
lization of MTs. This increase in stability could, 
therefore, explain the resistance to drugs such as 
colchicine and vinblastine which destabilize MTs 
and the increased sensitivity to those drugs like 
paclitaxel and epothilone that cause MT stabiliza-
tion. This is most likely a result of D45 location 
within a loop connecting helix 1 (H1) with β-sheet 
2 (S2), which was predicted to be a critical contact 
between tubulin dimers within protofilaments 
(Figure 5b) (Li et al. 2002). This position is not 
close to the site where colcemid binds to tubulin 
and it is, therefore, unlikely to act by changing the 
afﬁ  nity of tubulin for the drug. Wang et al. (2004) 
also identiﬁ  ed several revertants of D45Y MT 
stabilization effects. V60 is also located in the H1-
S2 loop and its replacement with alanine results in 
the reduction of MT assembly rates, thereby 
conferring resistance to paclitaxel. These authors 
observed that when D45Y and V60A substitutions 
are co-expressed, their individual effects on MT 
assembly result in a normal phenotype. Because 
both of these substitutions are found at a critical 
location for protofilament assembly, it is not 
surprising that they display such a marked effect 
on MT stability. An additional suppressor of the 
D45Y phenotype, Q292 was also identiﬁ  ed by 
Wang et al. (2004) to confer resistance to pacli-
taxel. This mutation resulted in the severe desta-
bilization of MTs and is located in H9, which is 
positioned near the M-loop which is involved in 
MT lateral interface interactions and the taxane 
binding site (Figure 5b). This position was also 
shown to become mutated within human tumor 
cell lines that became resistance to desoxyepothi-
lone B and epothilone B (Verrills et al. 2003; Yang 
et al. 2005).
V60. As discussed above, mutations at V60 
were observed under two separate studies which-
both resulted in decreased MT stability and reduced 
assembly rates and a requirement for paclitaxel or 
epothilone presence for growth (Wang et al. 2004; 
Yang et al. 2005). This mutation was originally 
identiﬁ  ed as a suppressor of D45Y. Residue V60 
is located at the end of the H1-S2 loop that has 
been implicated as a principal partner of the 
M loop for contacts between protofilaments 
(Figure 5b). A mutation at residue 60 could poten-
tially inhibit the lateral contacts between protoﬁ  la-
ments, resulting in the destabilization of MTs and 
is not predicted to confer altered drug binding.
D197N/K350N. 2-Methoxyestradiol is a potent 
anticancer agent that is thought to result in the 
destabilization of MT dynamics through its binding 
at the colchicine binding site (D’Amato et al. 
1994). Cells expressing both the D197N and 
K350N mutations simultaneously became resistant 
to 2-Methoxyestradiol, colchicine and vinca 
alkaloids (Gokmen-Polar et al. 2005). This obser-
vation was suggestive of a global stabilization of 
the MT structure with no effect on drug binding, 
due to the different binding sites for vinblastine 
and colchicine. Additionally, while these cells were Cancer Informatics 2007:3 176
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resistant to MT destabilizing drugs, they did not 
appear to be sensitive to MT stabilizing drugs such 
as Taxol.
Several interactions for K350 and D197 illus-
trate a possible structural basis of the resistance 
to 2-methoxyestradiol when either is mutated to 
asparagine. First, K350 is not only located near 
the colchicine binding site, but it also makes 
critical longitudinal contacts with α tubulin as it 
is buried at the intra-dimer interface (Figure 6a). 
Large differences in IC50 values for both colchi-
cine and vinblastine binding also suggested that 
drug binding was not affected as these two 
compounds bind at different sites within β-tubulin 
(Gigant et al. 2005). K350 may play a minor role 
in stabilizing the α-phosphate moiety of GTP 
bound tubulin, as it is only 6–7 Angstroms away. 
Because it is in close proximity to the colchicine 
binding site, K350’s participation in direct interac-
tions with colchicine cannot be ruled out 
entirely.
Unlike K350, which forms bonds with portions 
of α-tubulin, all of the local interactions for D197 
reside within β tubulin itself. D197, which resides 
at the end of S6, participates in a series of hydrogen 
bonds that are identical in both the straight and 
curved conformations of tubulin (Figure 5b) (Wang 
and Nogales, 2005). None of these hydrogen bonds 
would be signiﬁ  cantly disrupted by the mutation 
of D197N. However, D197 does participate in a 
salt bridge with R156 within H4. Removal of this 
salt bridge would most likely lead to a loss of 
anchoring of H4 and alter the propagation of 
conformational changes within β-tubulin, thereby 
inﬂ  uencing MT stability.
R306. Substitutions at position R306 were 
identiﬁ  ed in cells from paclitaxel resistant tumors 
(Hasegawa et al. 2002). While this substitution did 
result in resistance to paclitaxel, there was no 
determination if this was due to the destabilization 
of the MT structure, or a direct impact on drug 
binding. However, this substitution lies within the 
longitudinal interface between protoﬁ  laments and 
interacts with residue D118 within the adjacent 
β-tubulin monomer (Figure 5b). This interaction 
could constitute an additional salt bridge that acts 
to stabilize the longitudinal interface between 
protoﬁ  laments. Substitution to threonine would 
result in the destruction of this interaction and 
could very possibly lead to an overall decrease in 
MT stability, thereby producing a mechanism of 
resistance to paclitaxel.
Y442. Identiﬁ  ed as a heterozygous mutation, 
most likely due to a lethal phenotype in the homo-
zygous case. Substitution of Y442C resulted in 
cells that were dependent on either paclitaxel or 
epothilone for growth (He et al. 2001). This obser-
vation is, once again, suggestive of a global change 
in MT stability and not simply a decrease in overall 
drug binding. This substitution occurs within the 
end of H12 in a region not resolved in the crystal 
structure of the α/β-tubulin heterodimer (Lowe et al. 
2001). It is generally accepted that this region 
makes up the most variable part of the tubulin 
isotype sequences and is commonly referred to as 
the C-terminal tail. This substitution is therefore 
most likely associated with the alterations of inter-
actions with MAPs or proteins involved in the post 
translational modification of the C-termini 
(Luduena, 1998).
Correlation Between β-Tubulin 
Isotype Expression and Mutations
We have examined the correlation between the 
positions of sequence differences associated 
with β-tubulin isotypes and the mutations 
described here. Of all 21 mutations, only four 
seem to correlate with residue differences 
between β-tubulin isotypes (Table 2, Figure 7). 
The first, at residue 45, is a conservative substi-
tution from aspartic to glutamic acid and would 
most likely not affect MT dynamics in the class 
βII-VIII, isotypes that carry it. Next within the 
human isotypes at position 172, we observed 
the presence of a normal serine residue in class 
βI-VI and βVIII isotypes. However, in class 
βVII this serine has been replaced by a leucine. 
As described above, this substitution results in 
the loss of a polar serine. As this residue has 
been shown to be phosphorylated during cell 
division, its loss would lead to the resulting 
stabilization of MTs into which it was incorpo-
rated (Fourest-Lieuvin et al. 2006). While the 
expression of class βVII has yet to be correlated 
with resistance to MT destabilizing compounds 
or increased MT stability, this is an avenue of 
experimentation worthy of future investigation. 
The mutant A231T was shown to confer pacli-
taxel or epothilone resistance onto cells that 
expressed it (Verrills et al. 2003). Cells 
expressing this mutation were also shown to 
exhibit greater levels of the class βIII isotype 
expression. As previously stated, the A231T Cancer Informatics 2007:3 177
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substitution is located on H7 within a highly 
hydrophobic region of the taxane binding site. 
In the case of class βVI isotype containing a 
leucine at position 231, we expect that this 
conservative substitution would not lead to a 
dramatic change in phenotype.
Finally, we feel that one of the most signifi-
cant observations we have made with regard to 
the correlation between an isotype sequence and 
an observed mutation is the presence of an 
A364S substitution within the class βIII and βV 
isotypes. A364T was shown to become resistant 
to paclitaxel but not epothilone (Giannakakou 
et al. 2000). This substitution occurs within the 
taxane binding site and makes up a portion of 
the hydrophobic floor upon which paclitaxel 
Table 2. Hot spots correlating between β-tubulin isotype sequences and β-tubulin mutations associated with 
acquired drug resistance. All residues identiﬁ  ed as being nonconserved among the Human β-Tubulin isotypes 
were compared with those identiﬁ  ed in Table 1. The isotypes in which the change occurs are identiﬁ  ed with the 
differing residues in parentheses.
Residue   Mutant  Mutant  Phenotype  β-tubulin Isotype Expression 
 45  D45Y  CN resistant  βI(D)   βII-VIII(E) 
172 S172A  CN  resistant  βI-VI,VIII(S)   βVII(L)β 
231 A231T  PTX  resistant  βI-V,VII,VIII(A)   βVI(L)
364 A364T  PTX  resistant  βI,VII(V)   βIII,V(S)   βII,IV,VI,VIII(A)
Correlation Between β-Tubuiln Isotypes and Mutations 
Figure 7. Location of mutations and nonconserved residues in mammalian β-tubulin. As in Figure 3, with the exception that the β-Tubulin 
surface has been removed to expose the underlying tertiary structure which is shown as a cyan cartoon. Here residues (F45, S172, A231 
and A364), which are observed as occurring in both human β-tubulin isotypes and mutations identiﬁ  ed in Table 1, are shown as red sticks 
in relation to paclitaxel (purple).Cancer Informatics 2007:3 178
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and docetaxel’s C13 side chain sits. The substi-
tution of A364S in either class βIII or βV 
isotypes would result in a similar situation to 
that for the A364T mutant, a polar residue in 
this normally hydrophobic surface. This obser-
vation is exciting as the A364T mutation alone 
was shown to impart selective paclitaxel resis-
tance. This, coupled with the observation that 
the expression of the class βIII tubulin isotype 
may be correlated with paclitaxel resistance, 
points to a possible mechanism and target for 
this resistance (Mozzetti et al. 2005).
Conclusions
Even with the vast quantity of data available to us, 
it is still not entirely clear what effect the expres-
sion of a particular β-tubulin isotype, or acquisition 
of point mutations has on the stability of cellular 
MTs and their relationship to drug resistance. Two 
possible models may explain the role that these 
two processes play in drug resistance. First, it may 
be possible that certain isotypes or mutations 
exhibit decreased drug binding to β-tubulin. 
However, our previous observations suggest that 
while this may contribute to drug resistance, it most 
likely plays a minimal role due to the lack of 
observable differences at the drug binding sites 
(Huzil et al. 2006).
A second mechanism would produce global 
conformational differences between β-isotypes or 
mutants, thereby attenuating MT dynamics, 
making them more or less stable. We feel that the 
most interesting observation that has come out of 
this examination of mutations within β-tubulin is 
that out of a total of ﬁ  fteen residues that are found 
within the binding sites for either taxanes, colchi-
cine or vinca alkaloids, only ﬁ  ve were deﬁ  nitively 
identified as having a direct impact on drug 
binding. Although the mutations we have identiﬁ  ed 
are close to the region implicated in the binding of 
paclitaxel, a number of observations indicate that 
altered paclitaxel binding is not responsible for 
drug resistance in these mutants. For example, β-
tubulin is reported to contain the taxane binding 
site, yet mutations conferring paclitaxel resistance 
occur with equal frequency in both α and β-tubulin 
and both groups of mutants exhibit similar proper-
ties (Minotti et al. 1991; Hari et al. 2003; Yang 
et al. 2005). Many paclitaxel-resistant mutants 
require the presence of the drug for cell division 
and, therefore, must clearly retain the ability to 
bind the drug. Also, paclitaxel-resistant mutants 
frequently exhibit increased sensitivity to drugs 
such as colchicine and vinblastine that bind to 
distinctly different sites. Instead of altered drug 
binding, we favor a mechanism in which paclitaxel 
binding alters the conformation of both the M-loop 
and the short loop connecting H6 and H7 of 
β-tubulin in such a way as to facilitate and stabilize 
protein-protein interactions important in the forma-
tion of MTs. Recent ﬁ  tting of the crystal structure 
of tubulin to a lower resolution map of the MT is 
consistent with the participation of the H6-H7 loop 
in both longitudinal and lateral contacts (Amos and 
Lowe, 1999). Because the mutations appear to 
destabilize MT assembly in the absence of any drug 
a direct effect on protein-protein interactions 
appears the more likely possibility.
This hypothesis is also supported by the recent 
observations of Xiao et al. (2006) who suggest 
that paclitaxel-binding may act to increase the 
energy associated with lateral and longitudinal 
interactions between tubulin dimers in the MT. 
Therefore changes within these surfaces would 
mitigate the action of energetic contributions of 
paclitaxel binding. Additionally, many of the 
mutations discussed here are not located within 
drug binding pockets at all, yet still confer drug 
resistance onto the cells in which they are found. 
In general we can consider that cells resistant to 
MT stabilizing drugs, such as the taxanes or 
epothilones, will produce less stable MTs in 
response. This is demonstrated by decreased drug 
induced MT stability and often a requirement on 
the drug for growth. Conversely, cells that become 
resistant to MT destabilizing drugs such as colchi-
cine or vinblastine will produce MTs with 
increased stability. We must, however, be cautious 
when examining the data available in the literature, 
as much of the experimental results have been 
obtained through in vivo screening and do not give 
us speciﬁ  c information about paclitaxel binding 
to β tubulin. We believe that the key to developing 
new drugs that target tubulin and disrupt MT 
dynamics is through a better understanding of MT 
dynamics at the molecular level and the role muta-
tions and isotype differences have on the dynamic 
properties of tubulin and the MT.
While it is clear that a substantial amount of work 
has to be done on obtaining speciﬁ  c binding data 
for drug binding to β-tubulin isoforms and mutants 
described here, the presence of minor variations 
within the structure of β-tubulin may provide us 
with a starting point for the development of novel Cancer Informatics 2007:3 179
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drugs, or in the derivatization of existing drugs in 
order to gain in increased speciﬁ  city or effect. This 
type of approach may also allow us to develop 
secondary treatments for cancer cell lines that have 
developed drug resistance as a result of standard 
chemotherapy treatments, due to mutations or 
altered expression levels. We feel that the most 
signiﬁ  cant mechanism leading to drug resistance, 
as a result of both isotype expression and acquired 
mutations has to do with interactions within the MT 
structure itself and less to do with altered drug 
binding. This observation provides us with a novel 
set of targets with which to begin designing drugs 
that target these “hot spots” in an effort to counter 
the effects that β-tubulin isotype expression or muta-
tions have on the development of drug resistance in 
these cells. We hope that the analysis presented here 
will provide deeper insights and perhaps a new 
direction for the future development of drugs that 
target crucial regions within the MT. It is our ulti-
mate goal to develop a new generation of drugs that 
will target variant tubulins and thereby help reduce 
the adverse side effects associated with their use.
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